LivaNova VITARIA Won't Reach U.S. Market
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- LivaNova launched a pivotal trial in 2018 for its VITARIA vagus nerve stimulator to treat heart failure, after the FDA designated the device a breakthrough.
- The trial used an adaptive design built with FDA input, enrolling patients 100 at a time with prespecified checkpoints that allowed early stopping for promising or dangerous signals.
- After enrolling 500 patients — half the planned maximum — an independent data and safety monitoring board told investigators in 2022 the trial should continue because signals weren't strong enough to indicate a stopping point.
- The FDA's breakthrough device program has helped bring nearly 200 innovative products to the U.S. market over the past decade, but VITARIA "wasn't going to be one of them," per STAT.
- Earlier vagus nerve stimulator trials for heart failure had already shown mixed results before LivaNova launched its study, making VITARIA a long-shot entrant from the start.
Why it matters: The VITARIA case shows that FDA's "breakthrough" label is a designation for promising technology, not a guarantee of approval — and for the heart failure patients who don't respond adequately to drugs, another device candidate falling short after similar vagus nerve stimulators already produced mixed results narrows an already limited pool of non-pharmaceutical options.
Ask SkimNews
